Designing GMP-friendly cell and gene therapy manufacturing processes
On demand

Designing GMP-friendly cell and gene therapy manufacturing processes

Wednesday 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET
Designing GMP-friendly cell and gene therapy manufacturing processes

The cell and gene therapy market is exploding with medicinal products approved across multiple markets, with more products expected to receive regulatory approval in the upcoming years. Whilst all of these advancements are encouraging, a number of challenges remain in the manufacture of these transformative therapies especially as we look to move to commercial scale production.

Preparing for upscaling of cell and gene therapy products should be considered early during the product development to ensure success in the clinic and this includes streamlining manufacturing processes, sourcing raw materials, and QC for cell and gene therapy products.

Watch this On Demand webinar for the presentation featuring:

  • Dr Michael Papadimitrious, Product Manager, Engineered T Cells, Miltenyi Biotec
  • Dr Brian Murphy, Head of Bioprocess Development, Celgene
  • Dr Xiuyan Wang, Assistant Director, Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center

During this on demand, you’ll have the opportunity to hear the critical points to consider when designing a manufacturing process for your clinical cell and gene therapy products, including:

  • How and when to utlilize GMP materials within your product’s development.
  • Understanding the impact of raw material selection on your process design and development.
  • How to optimize your manufacturing process to suit your cell and gene therapy production needs
  • Learnings from experienced leads in the field of cell and gene therapy

Michael Papadimitrious
Michael Papadimitrious
Product Manager at Miltenyi Biotec
Michael is the Product Manager for Clinical Engineered T Cells at Miltenyi Biotec located in Germany. He obtained his PhD from The University of Sydney where he transfected human dendritic cells with tumor antigen IVT-mRNA and observed tumor antigen specific T cell immune responses. Prior to his PhD, he worked in Adelaide where he characterized novel monoclonal antibodies to be used for immune therapies.
Xiuyan Wang
Xiuyan Wang
Assistant Director, Michael G. Harris Cell Therapy & Cell Engineering Facility at

Dr. Wang was trained by Dr. Adolfo García-Sastre and received her Ph.D. in Biomedical Sciences from the Mount Sinai School of Medicine in New York. She joined Dr. Peter Cresswell’s laboratory in the Department of Immunology at Yale University as a Howard Hughes Medical Institute fellow, and later as a Cancer Research Institute postdoctoral associate.

Dr. Wang joined Memorial Sloan Kettering Cancer Center in 2007, and is currently the Associate Director of the Michael G Harris Cell Therapy and Cell Engineering Facility, and an Associate Lab Member in the Department of Molecular Pharmacology. Dr. Wang is in charge of the R&D, process development and manufacturing.

She has overseen the successful manufacturing of all the CAR T cell products used in 13 phase I/II clinical trials, over 20 batches of cGMP grade viral vectors, as well as tech transfers to multiple industrial partners. She served in the translational science and product development committee in the American Society of Gene and Cell Therapy (ASGCT). She is currently a member for the National Heart, Lung and Blood Institute (NHLBI) independent external expert panel and a committee member for the Alliance of Regenerate Medicine (ARM) and the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL).

Brian Murphy
Brian Murphy
Director, Bioprocess Development at Celgene Corporation
Brian Murphy is currently Director of Global Manufacturing Science and Technology at Celgene in Warren, NJ. His group is responsible for the technology transfer, qualification, and lifecycle management of cellular therapies. Over the past decade at Celgene, Brian has worked on developing, optimizing, and scaling up cell isolation, expansion, and formulation processes for MSC, NK, and CAR-T cell products. Prior to joining Celgene, he worked in the Merck Manufacturing Division and provided engineering support for the plant start-up of the Biotechnology Manufacturing Center and for the manufacture of recombinant vaccines. With great appreciation for both scientific research and commercial practicality, Brian is currently focused on the challenge of developing novel therapeutics and processes into commercial products. Brian holds a B.S. in Chemical Engineering from Cornell University, and a M.S./PhD in Chemical and Biomolecular Engineering from the University of Pennsylvania.